{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:32:17Z","timestamp":1792733537654,"version":"4.5.0"},"reference-count":44,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/objectives: Coronavirus-19 (COVID-19) vaccines represent a significant milestone in the fight against coronavirus disease. Ongoing post-marketing surveillance and research are crucial for ensuring vaccine safety and effectiveness, aiding public health planning. Methods: Our retrospective cohort study included Albertans five years and older and vaccinated with at least one dose of an approved COVID-19 vaccine between 14 December 2020 and 30 April 2022. This epidemiological study aimed to determine the incidence of reported adverse events following immunization (AEFI) in Alberta and identify associated risk factors. Results: The study included 3,527,106 vaccinated Albertans who met the study inclusion criteria. A total of 2541 individuals (72.0 per 100,000) reported an AEFI, with 2759 adverse events, most of which occurred following the first dose of vaccine and within the first week post-vaccination. Of these, 70.4% were female, and the highest incidence was in the 35\u201354 age group. Given that mRNA vaccines were predominantly administered across Canada, we report AEFI rates (per 100,000 doses) for the mRNA vaccine brands at 27.7 for Pfizer and 40.7 for Moderna. Allergic events were the most frequently reported AEFI, followed by adenopathy. Logistic regression analysis indicated that sex (with females at higher risk), presence of comorbidities, days to symptom onset, vaccine type (mRNA vs. mixed doses), and the number of doses were significant factors associated with an AEFI event. Conclusions: Our study provides valuable information to guide policies surrounding COVID-19 vaccination. While the risk of serious adverse events was low in the population-based sample, further research is warranted to identify and investigate other possible risk factors that are still unknown.<\/jats:p>","DOI":"10.3390\/vaccines12121409","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T05:55:45Z","timestamp":1734069345000},"page":"1409","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reported Adverse Events Following SARS-CoV-2 Vaccinations in the Canadian Province of Alberta and Associated Risk Factors: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"12","author":[{"given":"Yei","family":"Mansou","sequence":"first","affiliation":[{"name":"School of Public Health, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N2Z4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahalakshmi","family":"Kumaran","sequence":"additional","affiliation":[{"name":"Public Health Surveillance and Informatics, Provincial Population and Public Health, Alberta Health Services, 10301 Southport Rd., Calgary, AB T2W1S7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Farmer","sequence":"additional","affiliation":[{"name":"Public Health Surveillance and Informatics, Provincial Population and Public Health, Alberta Health Services, 10301 Southport Rd., Calgary, AB T2W1S7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Kemp","sequence":"additional","affiliation":[{"name":"Public Health Surveillance and Informatics, Provincial Population and Public Health, Alberta Health Services, 10301 Southport Rd., Calgary, AB T2W1S7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussain","family":"Usman","sequence":"additional","affiliation":[{"name":"Provincial Population and Public Health, Alberta Health Services, 10301 Southport Rd., Calgary, AB T2W1S7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Strong","sequence":"additional","affiliation":[{"name":"Provincial Population and Public Health, Alberta Health Services, 10301 Southport Rd., Calgary, AB T2W1S7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George K.","family":"Mutwiri","sequence":"additional","affiliation":[{"name":"School of Public Health, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N2Z4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khokan C.","family":"Sikdar","sequence":"additional","affiliation":[{"name":"Public Health Surveillance and Informatics, Provincial Population and Public Health, Alberta Health Services, 10301 Southport Rd., Calgary, AB T2W1S7, Canada"},{"name":"Community Health Sciences, Cumming School of Medicine, University of Calgary, 3330 Hospital Dr., Calgary, AB T2N4N1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"key":"ref_1","unstructured":"Johns Hopkins University (2024, September 19). Mortality Analyses. Available online: https:\/\/coronavirus.jhu.edu\/data\/mortality."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"E870","DOI":"10.1503\/cmaj.220316","article-title":"Canada\u2019s response to the initial 2 years of the COVID-19 pandemic: A comparison with peer countries","volume":"194","author":"Razak","year":"2022","journal-title":"Cmaj"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.14745\/ccdr.v50i12a05","article-title":"COVID-19 outcome trends by vaccination status in Canada, December 2020\u2013January 2022","volume":"50","author":"Dam","year":"2024","journal-title":"Can. Commun. Dis. Rep."},{"key":"ref_4","unstructured":"Government of Canada (2024, October 03). Vaccines for COVID-19. Available online: https:\/\/www.canada.ca\/en\/public-health\/services\/diseases\/coronavirus-disease-covid-19\/vaccines.html."},{"key":"ref_5","unstructured":"Government of Canada (2023, March 26). COVID-19 Vaccination in Canada: Vaccination Coverage. Available online: https:\/\/health-infobase.canada.ca\/covid-19\/vaccination-coverage\/."},{"key":"ref_6","unstructured":"WHO, World Health Organization (2024, December 01). COVID-19 Vaccines: Safety Surveillance Manual. Available online: https:\/\/www.who.int\/docs\/default-source\/covid-19-vaccines-safety-surveillance-manual\/covid19vaccines_manual_aefi_20210104.pdf."},{"key":"ref_7","unstructured":"Government of Canada (2023, March 17). Reported Side Effects Following COVID-19 Immunizations in Canada: Summary of Adverse Events Following Immunization Report. Available online: https:\/\/health-infobase.canada.ca\/covid-19\/vaccine-safety\/#a4."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/jcmm.17137","article-title":"Cardiovascular and haematological events post COVID-19 vaccination: A systematic review","volume":"26","author":"Elshafeey","year":"2022","journal-title":"J. Cell Mol. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e059223","DOI":"10.1136\/bmjopen-2021-059223","article-title":"Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: A systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature","volume":"12","author":"Lane","year":"2022","journal-title":"BMJ Open"},{"key":"ref_10","unstructured":"Public Health Agency of Canada (2024, November 04). Canadian COVID-19 Vaccination Safety Report. Available online: https:\/\/health-infobase.canada.ca\/covid-19\/vaccine-safety\/."},{"key":"ref_11","unstructured":"Ontario Agency for Health Protection and Promotion (Public Health Ontario) (2024). Adverse Events Following Immunization (AEFIs) for COVID-19 in Ontario: December 13, 2020 to May 19, 2024, King\u2019s Printer for Ontario."},{"key":"ref_12","unstructured":"Government of Nova Scotia (2024, October 11). Adverse Events Following Immunization (AEFI) with COVID-19 Vaccines in Nova Scotia December 16, 2020 to November 30. Available online: https:\/\/novascotia.ca\/coronavirus\/docs\/adverse-events-following-immunization-with-COVID-19-vaccines-2021-11-30.pdf."},{"key":"ref_13","unstructured":"Government of Saskatchewan (2024, October 11). Summary of COVID-19 Vaccine AEFI Reports Received in Saskatchewan. Available online: https:\/\/www.saskatchewan.ca\/government\/health-care-administration-and-provider-resources\/treatment-procedures-and-guidelines\/public-health-issues\/respiratory-illnesses\/covid-19\/covid-19-vaccine\/covid-19-vaccine-information\/covid-19-vaccine-details\/summary-of-covid-19-vaccine-aefi-reports-received-in-saskatchewan."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/cid\/ciac852","article-title":"Adverse events following immunization with mRNA and viral vector vaccines in individuals with previous severe acute respiratory syndrome coronavirus 2 infection from the Canadian national vaccine safety network","volume":"76","author":"Bettinger","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","unstructured":"Alberta Health Services (2022, May 10). Meditech Clinical Information System (CIS). Available online: https:\/\/www.albertahealthservices.ca\/info\/Page10995.aspx."},{"key":"ref_16","unstructured":"Government of Alberta (2022, November 24). Adverse Events Following Immunization (AEFI) Policy for Alberta Immunization Providers. Available online: https:\/\/open.alberta.ca\/dataset\/d86b52a9-45f4-4948-8a06-53b2c045135e\/resource\/7c04e283-dcf2-442f-98a7-025902e65ba2\/download\/health-aip-adverse-events-following-immunization-policy-2022-07.pdf."},{"key":"ref_17","unstructured":"Government of Alberta (2022, July 18). Welcome to Alberta Vaccine Inventory (AVI). Available online: https:\/\/vimsavi.alberta.ca\/prod\/."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJMoa2110362","article-title":"Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings","volume":"385","author":"Thompson","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_19","unstructured":"Alberta Health Services (2022, May 10). AHS Map and Zones Overview. Available online: https:\/\/www.albertahealthservices.ca\/assets\/about\/publications\/ahs-ar-2021\/zones.html."},{"key":"ref_20","unstructured":"Government of Alberta (2024, October 09). Welcome to the Interacative Health Data Application, Available online: http:\/\/www.ahw.gov.ab.ca\/IHDA_Retrieval\/."},{"key":"ref_21","unstructured":"CDC, Centre for Disease Control (2024, November 28). Underlying Conditions and the Higher Risk for Severe COVID-19, Available online: https:\/\/www.cdc.gov\/covid\/hcp\/clinical-care\/underlying-conditions.html."},{"key":"ref_22","unstructured":"Public Health Agency of Canada (2022, January 17). Canadian Adverse Events Following Immunizations Surveillance Systems (CAEFISS). Available online: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/vaccines-immunization\/adverse-events-following-immunization-bi-annual-report-january-1-june-30-2019.html."},{"key":"ref_23","unstructured":"Government of Alberta (2024, November 22). Active Surveillance and Reporting of Adverse Events Following Immunization (AEFI). Available online: https:\/\/open.alberta.ca\/dataset\/4d885a4c-f9b3-4434-bf5a-5accb63e22a1\/resource\/817428f3-0b65-4f43-90db-fa5f7e368b3d\/download\/health-aip-aefi-covid-19-2022-02-25.pdf."},{"key":"ref_24","unstructured":"IBM Corp. (2017). IBM SPSS Statistics for Windows, Version 25.0, IBM Corp."},{"key":"ref_25","first-page":"e23526","article-title":"Pfizer-BioNTech COVID-19 vaccine (BNT162b2) side effects: A systematic review","volume":"14","author":"Dighriri","year":"2022","journal-title":"Cureus"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.resinv.2021.06.003","article-title":"Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan","volume":"59","author":"Izumo","year":"2021","journal-title":"Respir. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"368504211025927","DOI":"10.1177\/00368504211025927","article-title":"COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A review of the potential mechanisms and proposed management","volume":"104","author":"Alam","year":"2021","journal-title":"Sci. Prog."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Bilotta, C., Perrone, G., Adelfio, V., Spatola, G.F., Uzzo, M.L., Argo, A., and Zerbo, S. (2021). COVID-19 vaccine-related thrombosis: A systematic review and exploratory analysis. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.729251"},{"key":"ref_30","first-page":"355","article-title":"Addressing vaccine-induced immune thrombotic thrombocytopenia (VITT) following COVID-19 vaccination: A mini-review of practical strategies","volume":"37","author":"Chen","year":"2021","journal-title":"Acta Cardiol. Sin."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/ane.13575","article-title":"Guillain-Barre syndrome following COVID-19 vaccines: A scoping review","volume":"145","author":"Fernandez","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Islam, A., Bashir, M.S., Joyce, K., Rashid, H., Laher, I., and Elshazly, S. (2021). An update on covid-19 vaccine induced thrombotic thrombocytopenia syndrome and some management recommendations. Molecules, 26.","DOI":"10.3390\/molecules26165004"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"577691","DOI":"10.1016\/j.jneuroim.2021.577691","article-title":"Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature","volume":"359","author":"Min","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"577719","DOI":"10.1016\/j.jneuroim.2021.577719","article-title":"AstraZeneca COVID-19 vaccine and Guillain- Barr\u00e9 Syndrome in Tasmania: A causal link?","volume":"360","author":"Oo","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.thromres.2022.04.020","article-title":"Thrombotic thrombocytopenic purpura (TTP) after COVID-19 vaccination: A systematic review of reported cases","volume":"214","author":"Saluja","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"117607","DOI":"10.1016\/j.jns.2021.117607","article-title":"Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review","volume":"428","author":"Bahmanyar","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"10760296211068487","DOI":"10.1177\/10760296211068487","article-title":"Thrombosis with thrombocytopenia syndrome after administration of AZD1222 or Ad26.COV2.S vaccine for COVID-19: A systematic review","volume":"27","author":"Waqar","year":"2021","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_38","first-page":"e19240","article-title":"Clinical presentation and outcomes of myocarditis post mRNA Vaccination: A meta-analysis and systematic review","volume":"13","author":"Matta","year":"2021","journal-title":"Cureus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"577765","DOI":"10.1016\/j.jneuroim.2021.577765","article-title":"A systematic review of cases of CNS demyelination following COVID-19 vaccination","volume":"362","author":"Ismail","year":"2022","journal-title":"J. Neuroimmunol."},{"key":"ref_40","unstructured":"Statistics Canada (2024, October 11). Demographic Estimates by Age and Gender, Provinces and Territories: Interactive Dashboard. Available online: https:\/\/www150.statcan.gc.ca\/n1\/pub\/71-607-x\/71-607-x2020018-eng.htm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"26335565211058037","DOI":"10.1177\/26335565211058037","article-title":"Multimorbidity in large Canadian urban centres: A multilevel analysis of pooled 2015-2018 cross-sectional cycles of the Canadian Community Health Survey","volume":"11","author":"Wilk","year":"2021","journal-title":"J Multimorb Comorb"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/2042098615615472","article-title":"Predicting risk of adverse drug reactions in older adults","volume":"7","author":"Lavan","year":"2016","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_43","unstructured":"World Health Organization, Uppsala Monitoring Centre (2024, December 02). The Use of the WHO-UMC System for Standardised Case Causality Assessment. Available online: https:\/\/www.who.int\/docs\/default-source\/medicines\/pharmacovigilance\/whocausality-assessment.pdf."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2796.1990.tb00199.x","article-title":"Drug related hospital admissions: The role of definitions and intensity of data collection, and the possibility of prevention","volume":"228","author":"Hallas","year":"1990","journal-title":"J. Intern. Med."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/12\/1409\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:54:17Z","timestamp":1760115257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/12\/1409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":44,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["vaccines12121409"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12121409","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]}}}